More striking, the presence of an early memory T-cell population in the pre-manufacturing leukapheresis product predicted, with 100% accuracy, responders vs. non-responders to CD19 CAR T therapy among CLL patients18. This evidence concerns the gene CD19 and B-cell chronic lymphocytic leukemia.